Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025Business Wire • 02/27/25
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/26/25
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and AwarenessPRNewsWire • 01/21/25
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/08/24
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024Business Wire • 10/31/24
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It AttractiveSeeking Alpha • 10/25/24
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 08/01/24
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024Business Wire • 07/25/24
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 07/24/24
Xeris Biopharma unveils CEO succession plan, John Shannon to lead companyProactive Investors • 07/08/24
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024Business Wire • 06/03/24
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)Business Wire • 05/30/24